Citation: New England Journal of Medicine. 376(5):451-460, 2017 02 02.Journal: The New England journal of medicine.Published: 2017ISSN: 0028-4793.Full author list: Rogers JG; Pagani FD; Tatooles AJ; Bhat G; Slaughter MS; Birks EJ; Boyce SW; Najjar SS; Jeevanandam V; Anderson AS; Gregoric ID; Mallidi H; Leadley K; Aaronson KD; Frazier OH; Milano CA.UI/PMID: 28146651.Subject(s): Adult | Aged | Disease-Free Survival | Heart Failure/mo [Mortality] | *Heart Failure/th [Therapy] | Heart-Assist Devices/ae [Adverse Effects] | *Heart-Assist Devices | Humans | Intention to Treat Analysis | Kaplan-Meier Estimate | Middle Aged | Prosthesis Design | Prosthesis Failure | Quality of Life | Stroke/et [Etiology]Institution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Comparative Study | Journal Article | Multicenter Study | Randomized Controlled Trial | Research Support, Non-U.S. Gov'tOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1056/NEJMoa1602954 (Click here)Abbreviated citation: N Engl J Med. 376(5):451-460, 2017 02 02.Local Holdings: Available online from MWHC library: 1993 - present, Available in print through MWHC library: 1980 - present.Abstract: Background Mechanical circulatory support with a left ventricular assist device (LVAD) is an established treatment for patients with advanced heart failure. We compared a newer LVAD design (a small intrapericardial centrifugal-flow device) against existing technology (a commercially available axial-flow device) in patients with advanced heart failure who were ineligible for heart transplantation. Methods We conducted a multicenter randomized trial involving 446 patients who were assigned, in a 2:1 ratio, to the study (centrifugal-flow) device or the control (axial-flow) device. Adults who met contemporary criteria for LVAD implantation for permanent use were eligible to participate in the trial. The primary end point was survival at 2 years free from disabling stroke or device removal for malfunction or failure. The trial was powered to show noninferiority with a margin of 15 percentage points. Results The intention-to treat-population included 297 participants assigned to the study device and 148 participants assigned to the control device. The primary end point was achieved in 164 patients in the study group and 85 patients in the control group. The analysis of the primary end point showed noninferiority of the study device relative to the control device (estimated success rates, 55.4% and 59.1%, respectively, calculated by the Weibull model; absolute difference, 3.7 percentage points; 95% upper confidence limit, 12.56 percentage points; P=0.01 for noninferiority). More patients in the control group than in the study group had device malfunction or device failure requiring replacement (16.2% vs. 8.8%), and more patients in the study group had strokes (29.7% vs. 12.1%). Quality of life and functional capacity improved to a similar degree in the two groups. Conclusions In this trial involving patients with advanced heart failure who were ineligible for heart transplantation, a small, intrapericardial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to survival free from disabling stroke or device removal for malfunction or failure. (Funded by HeartWare; ENDURANCE ClinicalTrials.gov number, NCT01166347 .).